X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (6) 6
female (6) 6
humans (6) 6
middle aged (6) 6
index medicus (5) 5
male (5) 5
oncology (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cisplatin - administration & dosage (3) 3
disease-free survival (3) 3
lung cancer (3) 3
neutropenia (3) 3
tumors (3) 3
adult (2) 2
analysis (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
cancer (2) 2
cancer therapies (2) 2
cancer vaccines - adverse effects (2) 2
cancer vaccines - therapeutic use (2) 2
carboplatin - administration & dosage (2) 2
carcinoma, non-small-cell lung - therapy (2) 2
chemotherapy (2) 2
cisplatin (2) 2
clinical trials (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease (2) 2
double-blind (2) 2
drug administration schedule (2) 2
gene (2) 2
hematology, oncology and palliative medicine (2) 2
immunotherapy (2) 2
kaplan-meier estimate (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - mortality (2) 2
membrane glycoproteins - adverse effects (2) 2
membrane glycoproteins - therapeutic use (2) 2
motivation (2) 2
pain (2) 2
patients (2) 2
product development (2) 2
proteins (2) 2
solid tumors (2) 2
treatment outcome (2) 2
1st-line treatment (1) 1
5-fluorouracil folinic acid and irinotecan (1) 1
5-fluorouracil folinic acid and oxaliplatin (1) 1
8-hydroxyguanine (1) 1
8-oxoguanine (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
abridged index medicus (1) 1
airway stenting (1) 1
anemia - etiology (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antigens (1) 1
antigens, cd - analysis (1) 1
antigens, differentiation, t-lymphocyte - analysis (1) 1
antimetabolites, antineoplastic (1) 1
antimetabolites, antineoplastic - administration & dosage (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, immunological - administration & dosage (1) 1
antineoplastic agents, immunological - adverse effects (1) 1
antineoplastic agents, phytogenic - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
apoptosis (1) 1
apurinic sites (1) 1
arthralgia (1) 1
b_open_article_in_toll_access_journal (1) 1
backache (1) 1
balugrastim (1) 1
base excision repair (1) 1
base excision-repair (1) 1
bayesian analysis (1) 1
bevacizumab (1) 1
bevacizumab - administration & dosage (1) 1
biomarkers (1) 1
biomarkers, tumor - blood (1) 1
biopsy (1) 1
biopsy, needle (1) 1
blood cell count (1) 1
breast cancer (1) 1
breast neoplasms - drug therapy (1) 1
bronchi (1) 1
bronchomalacia (1) 1
bronchoscopy (1) 1
camptothecin - adverse effects (1) 1
camptothecin - analogs & derivatives (1) 1
camptothecin - therapeutic use (1) 1
cancer vaccines (1) 1
carboplatin (1) 1
carboplatin - adverse effects (1) 1
carcinoma (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1125 - 1133
Summary Background Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on... 
Hematology, Oncology and Palliative Medicine | DOUBLE-BLIND | PROGNOSTIC-FACTORS | GENE | ONCOLOGY | EXPRESSION | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vaccinia virus - genetics | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Risk Assessment | Deoxycytidine - administration & dosage | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Cancer Vaccines - adverse effects | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Interleukin-2 - genetics | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucin-1 - immunology | Vaccines, Synthetic | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Mucin-1 - genetics | Index Medicus | Interleukin-2 | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Cancer Vaccines | Membrane Glycoproteins | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Mucin-1 | Vaccinia virus | Deoxycytidine | Antimetabolites, Antineoplastic | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
by Paz-Ares, Luis and Dvorkin, Mikhail and Chen, Chengshui and Chen, Yen-Hsun and Chen, Yuan and Chen, Yuanbin and Chen, Zhendong and Reinmuth, Niels and Hotta, Katsuyuki and Trukhin, Dmytro and Statsenko, Galina and Hochmair, Maximilian J and Özgüroğlu, Mustafa and Ji, Jun Ho and Voitko, Nataliia and Voitko, Oleksandr and Poltoratskiy, Artem and Ponce, Santiago and Verderame, Francesco and Havel, Libor and Bondarenko, Igor and Kazarnowicz, Andrzej and Losonczy, György and Conev, Nikolay V and Armstrong, Jon and Byrne, Natalie and Shire, Norah and Jiang, Haiyi and Goldman, Jonathan W and Batagelj, Emilio and Casarini, Ignacio and Pastor, Anea Viviana and Sena, Susana Noemi and Zarba, Juan Jose and Burghuber, Otto and Hartl, Sylvia and Lamprecht, Bernd and Studnicka, Michael and Alberto Schlittler, Luis and Augusto Martinelli de Oliveira, Fabricio and Calabrich, Aknar and Colagiovanni Girotto, Gustavo and Dos Reis, Peo and Fausto Nino Gorini, Carlos and Rafael Martins De Marchi, Peo and Serodio da Rocha Baldotto, Clarissa and Sette, Claudia and Zukin, Mauro and Dudov, Assen and Ilieva, Rumyana and Koynov, Krassimir and Krasteva, Rositsa and Tonev, Ivan and Valev, Spartak and Venkova, Violetka and Bi, Minghong and Fang, Jian and Feng, Jifeng and Han, Zhigang and Hu, Jie and Hu, Yi and Li, Wei and Li, Chien-Te and Liang, Zongan and Lin, Zhong and Ma, Shenglin and Ma, Rui and Nan, Kejun and Shu, Yongqian and Wang, Chin-Chou and Wang, Kai and Wang, Mengzhao and Wu, Gang and Wu, Shang-Yin and Yang, Nong and Yang, Zhixiong and Zhang, Wei and Zhang, Helong and Zhao, Yanqiu and Zhao, Jun and Zhou, Jianying and Zhou, Caicun and Zhou, Xiangdong and Kolek, Vitezslav and Koubkova, Leona and Roubec, Jaromir and Skrickova, Jana and Zemanova, Milada and Chouaid, Christos and Hilgers, Werner and Lena, Hervé and Moro-Sibilot, Denis and Robinet, Gilles and Souquet, Pierre-Jean and Alt, Jürgen and Bischoff, Helge and Grohe, Christian and Laack, Eckart and Lang, Susanne and Panse, Jens and ... and CASPIAN Investigators and CASPIAN investigators
The Lancet, ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1929 - 1939
Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has... 
PROPHYLACTIC CRANIAL IRRADIATION | SCLC | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | CISPLATIN | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Etoposide - adverse effects | Drug Administration Schedule | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols | Carboplatin - administration & dosage | Etoposide - administration & dosage | Male | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Carboplatin - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Progression-Free Survival | Cisplatin - adverse effects | Female | Small Cell Lung Carcinoma - mortality | Aged | Etoposide | Care and treatment | Product development | Lung cancer | Analysis | Drugs | Medical services | Radiation | Clinical trials | Metastasis | Cancer therapies | Randomization | Motivation | Platinum | Immunotherapy | Safety | Neutropenia | Small cell lung carcinoma | Maintenance | Radiation therapy | Survival | Patients | Cisplatin | Response rates | Carboplatin | Irradiation | Ligands | Clinical medicine | Solid tumors | Tumors | Apoptosis
Journal Article
Cancer Medicine, ISSN 2045-7634, 05/2018, Volume 7, Issue 5, pp. 1660 - 1669
Journal Article
World Journal of Gastroenterology, ISSN 1007-9327, 2010, Volume 16, Issue 25, pp. 3133 - 3143
Journal Article
Chest, ISSN 0012-3692, 10/2003, Volume 124, Issue 4, p. S124
Journal Article
Chest, ISSN 0012-3692, 10/2003, Volume 124, Issue 4, p. S124
Journal Article
Journal Article
Chest, ISSN 0012-3692, 10/2000, Volume 118, Issue 4, p. 93
Journal Article
Chest, ISSN 0012-3692, 10/1999, Volume 116, Issue 4, p. 264
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.